Rewriting human aging with Physics and AI with Dr. Peter Fedichev of Gero (Part 2)

<p>Dr. Peter Fedichev is the co-founder and CEO of <strong>GERO</strong>, a Singapore-based biotech startup that uses physics-informed AI and massive human health datasets to discover drugs aimed at slowing down aging and treating age-related diseases.</p><p>In the 2nd part of this episode, Peter explains how Gero builds generative models of human health to predict disease trajectories and identify shared biological drivers across multiple chronic conditions. He discusses why metabolic dysfunction and inflammation represent promising intervention points, how partnerships with pharma companies like Chugai accelerate translation, and why companion dogs could become the proving ground for longevity therapeutics.</p><p>Peter also shares his perspective on AI-driven drug discovery, arguing that target identification, not molecule generation, will create the greatest value. He outlines Gero’s open-source approach, fundraising journey, and vision for a future where therapies can meaningfully slow the aging process itself.</p><p><br></p><p>Host: John Joson Ng</p><p>Editors: Dillon Chew, Chi Dam, Vasilina Gedzun</p><p><br></p><p>00:00 Gero Roadmap Overview</p><p>00:35 Predicting Disease Trajectories</p><p>03:03 Super Targets Strategy</p><p>05:07 Ozempic Market Wakeup</p><p>07:28 Binary Strategy With Pharma</p><p>10:11 Gerosense Wearable Aging API</p><p>11:58 Crossdisciplinary Lab Workflow</p><p>14:09 ProtoBind Diff Explained</p><p>17:16 Open Source Business Logic</p><p>21:10 Chugai Partnership Begins</p><p>23:57 AI Push In Big Pharma</p><p>27:09 Funding Gero Early</p><p>31:38 Differentiating From Calico and Altos</p><p>35:56 Longevity Roadmap Dogs To Humans</p><p>42:36 Next Milestones For Gero</p><p>43:45 Personal Motivation To Fight Aging</p>